Brainsway Ltd. BRSYF

Company Overview

BrainsWay Ltd. is an Israel-based medical device company focused on noninvasive neurostimulation therapies for mental health and neurological disorders. The company develops and commercializes transcranial magnetic stimulation (TMS) systems using its proprietary Deep TMS technology, which is designed to stimulate broader and deeper regions of the brain than conventional TMS systems. BrainsWay operates primarily within the medical technology, psychiatry, neurology, and digital health sectors, with revenue driven mainly through sales and leasing of Deep TMS systems, treatment coils, service agreements, and recurring disposable components used by healthcare providers.

The company’s principal customer base includes psychiatric clinics, hospitals, academic medical centers, and specialty mental health practices. BrainsWay’s systems have received regulatory clearances for multiple indications, including major depressive disorder, obsessive-compulsive disorder, smoking addiction, and anxious depression in certain jurisdictions. The company originated from research conducted at the National Institute for Psychobiology in Israel and was formally established in 2003. Over time, it evolved from a research-stage neurotechnology developer into a commercial-stage medical device company with regulatory approvals in North America, Europe, and other international markets. Its strategic positioning centers on clinically validated Deep TMS technology, an expanding intellectual property portfolio, and a growing installed base in psychiatric care settings.

Business Operations

BrainsWay organizes its operations primarily around the commercialization of its Deep TMS platform and associated treatment technologies. The company generates revenue through direct system sales, operating leases, recurring treatment session consumables, maintenance contracts, and service-related income. Its core assets include proprietary H-Coil technology, software systems for treatment administration, and a portfolio of patents related to magnetic stimulation therapies. The company’s operational focus is heavily concentrated in mental health treatment markets, particularly depression and obsessive-compulsive disorder, while also pursuing additional neurological and addiction-related applications.

The company operates internationally, with significant commercial emphasis in the United States, which represents its largest revenue market, alongside activities across Europe, Israel, and selected regions in Asia-Pacific. BrainsWay maintains relationships with psychiatric treatment networks, healthcare providers, and research institutions conducting clinical studies involving Deep TMS applications. The company also works with distributors and commercial partners in certain international markets to support system deployment, physician training, and clinical adoption. Public filings and investor materials indicate that BrainsWay continues investing in clinical evidence generation to support reimbursement expansion and regulatory approvals.

Strategic Position & Investments

BrainsWay’s strategic direction centers on expanding clinical indications for Deep TMS therapy, increasing market penetration within psychiatric care, and strengthening reimbursement coverage from public and private insurers. The company has pursued growth through continued clinical trials, regulatory submissions, physician education programs, and broader commercialization efforts in behavioral health treatment. Its strategy also includes enhancing recurring revenue streams tied to consumables and long-term customer service agreements associated with installed systems.

The company has invested in expanding applications for Deep TMS beyond depression into addiction, anxiety-related disorders, and neurological conditions. BrainsWay has also pursued collaborations with clinical researchers and healthcare institutions to validate treatment efficacy across additional indications. While the company has not historically relied on large-scale acquisitions compared with larger medical device peers, it has emphasized internal technology development and intellectual property expansion as core competitive drivers. Public disclosures indicate ongoing investment in research and development aimed at advancing next-generation stimulation protocols and improving treatment accessibility.

Geographic Footprint

BrainsWay is headquartered in Jerusalem, Israel, and maintains a substantial operational and commercial presence in the United States, including activities related to sales, reimbursement support, clinical training, and customer service. The company’s products are marketed across multiple international regions through direct operations and distributor relationships. Regulatory clearances in the United States, European Union, and other jurisdictions have enabled broader market access for its Deep TMS systems.

The company’s commercial footprint spans North America, Europe, parts of Asia-Pacific, and selected additional international markets. The U.S. market remains strategically important due to reimbursement dynamics, psychiatric treatment demand, and the concentration of commercial installations. BrainsWay’s international influence is also supported by clinical collaborations and published research involving healthcare institutions across several countries, contributing to physician adoption and broader recognition of Deep TMS technology within psychiatric medicine.

Leadership & Governance

BrainsWay is governed by a board of directors and executive leadership team with backgrounds spanning medical technology, healthcare commercialization, neuroscience, finance, and clinical research. The company’s leadership strategy has emphasized expanding reimbursement access, increasing physician adoption, strengthening clinical evidence, and scaling commercial operations in major healthcare markets. Public corporate communications and regulatory filings consistently highlight innovation in neurostimulation therapies and long-term growth through evidence-based psychiatric treatment solutions.

Key executives include:

• Hadar Levy – Chief Executive Officer
• Ronen Faier – Chairman of the Board
• Yossi Bornstein – Chief Financial Officer
• Dr. Yiftach Roth – Chief Medical Officer
• Guy Ezekiel – Chief Commercial Officer

Information regarding leadership roles and governance structure has been verified through SEC filings, company investor relations materials, and public corporate disclosures. Some executive role assignments may change over time based on subsequent corporate announcements or filings.